14.67

7.15% 0.96

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $14.67, with a volume of 1.41M. It is up +7.15% in the last 24 hours and up +11.29% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$13.71

Open:

$13.9

24h Volume:

1.41M

Relative Volume:

0.82

Market Cap:

$4.68B

Revenue:

$3.05B

Net Income/Loss:

$181.32M

P/E Ratio:

39.26

EPS:

0.3737

Net Cash Flow:

$225.64M

1W Performance:

+16.13%

1M Performance:

+11.29%

6M Performance:

+22.73%

1Y Performance:

+93.04%

1-Day Range:

$13.79

$14.70

1-Week Range:

$12.49

$14.70

52-Week Range:

$7.53

$15.42

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2026-05-01

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	14.66	4.37B	3.05B	181.32M	225.64M	0.3737
TAK Takeda Pharmaceutical Co Adr	15.79	49.73B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.115	39.25B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.03	38.73B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.67	33.04B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	551.84	23.12B	3.17B	1.29B	1.01B	27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	UBS	Buy
Dec-09-25	Initiated	Barclays	Overweight
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

11:53 AM

What's Driving Amneal's 2026 Growth Outlook? - TradingView

11:53 AM

Jun 08, 2026

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN

Jun 08, 2026

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News

Jun 08, 2026

Jun 07, 2026

Why Amneal (AMRX) stock is trading up today - MSN

Jun 07, 2026

Jun 06, 2026

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm

Jun 06, 2026

How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations - Yahoo Finance

Jun 06, 2026

Jun 05, 2026

Amneal reports interim data on Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa

Jun 05, 2026

Amneal reports interim data for Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa

Jun 05, 2026

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail

Jun 05, 2026

Amneal reports interim data on Parkinson’s drug CREXONT - Investing.com UK

Jun 05, 2026

Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative

Jun 05, 2026

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - The Manila Times

Jun 05, 2026

Parkinson’s study: CREXONT adds over 3 hours of daily 'Good On' time - Stock Titan

Jun 05, 2026

Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo

Jun 05, 2026

AMRX News | AMNEAL PHARMACEUTICALS INC (NASDAQ:AMRX) - ChartMill

Jun 05, 2026

Amneal Stock Up on FDA Approval of Romidepsin Injection for Lymphoma PatientsNews and Statistics - IndexBox

Jun 05, 2026

Jun 04, 2026

Why Amneal (AMRX) Stock Is Trading Up Today - Yahoo Finance UK

Jun 04, 2026